Pharmacological management of PCOS: trends and insights from a 10-year bibliometric analysis.

IF 2.5 3区医学 Q3 PHARMACOLOGY & PHARMACY

Expert Opinion on Pharmacotherapy Pub Date : 2025-07-15 DOI:10.1080/14656566.2025.2535175

Rohit Gautam, Anshu Jyoti, Asmitha Bhateja, Neena Malhotra, Taruna Arora

{"title":"Pharmacological management of PCOS: trends and insights from a 10-year bibliometric analysis.","authors":"Rohit Gautam, Anshu Jyoti, Asmitha Bhateja, Neena Malhotra, Taruna Arora","doi":"10.1080/14656566.2025.2535175","DOIUrl":null,"url":null,"abstract":"Background: PCOS is an endocrine disorder affecting women of reproductive aged group. It has multiple manifestations including metabolic, reproductive, and psychological domains. Among PCOS patient's pharmaceutical management remains a primary approach to its treatment, particularly when lifestyle changes do not yield improvements.Objective: This study aims to highlight trends in global research concerning PCOS and its pharmacological treatment within the last decade using bibliometric analysis.Methods: A bibliometric analysis was conducted for the 2015-2024 timeframe using Web of Science database. Search queries were designed on PCOS as well its pharmacological treatment options. Data analysis was performed through visualization of collaborations, research trends etcin VOS viewer.Results: 2607 publications qualified for inclusion criteria. The most frequently treated topics were combined oral contraceptives, metformin, letrozole and inositols. China is the leading contributor toward publication volume while the U.S.A. was most cited and had the strongest links. Influence appeared to stem from Monash University whose Legro RS was deemed the most influential institution and there alongside the most impactful author.Conclusion: The study reveals global trends in PCOS pharmacotherapy, with growing focus on metabolic and molecular aspects. Key contributors and emerging therapies highlight the expanding scope and future potential of PCOS treatment research.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14656566.2025.2535175","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: PCOS is an endocrine disorder affecting women of reproductive aged group. It has multiple manifestations including metabolic, reproductive, and psychological domains. Among PCOS patient's pharmaceutical management remains a primary approach to its treatment, particularly when lifestyle changes do not yield improvements.

Objective: This study aims to highlight trends in global research concerning PCOS and its pharmacological treatment within the last decade using bibliometric analysis.

Methods: A bibliometric analysis was conducted for the 2015-2024 timeframe using Web of Science database. Search queries were designed on PCOS as well its pharmacological treatment options. Data analysis was performed through visualization of collaborations, research trends etcin VOS viewer.

Results: 2607 publications qualified for inclusion criteria. The most frequently treated topics were combined oral contraceptives, metformin, letrozole and inositols. China is the leading contributor toward publication volume while the U.S.A. was most cited and had the strongest links. Influence appeared to stem from Monash University whose Legro RS was deemed the most influential institution and there alongside the most impactful author.

Conclusion: The study reveals global trends in PCOS pharmacotherapy, with growing focus on metabolic and molecular aspects. Key contributors and emerging therapies highlight the expanding scope and future potential of PCOS treatment research.

查看原文本刊更多论文

多囊卵巢综合征的药物管理：10年文献计量学分析的趋势和见解。

背景：多囊卵巢综合征是一种影响育龄妇女的内分泌疾病。它有多种表现，包括代谢、生殖和心理领域。在多囊卵巢综合征患者中，药物管理仍然是治疗多囊卵巢综合征的主要方法，特别是当生活方式的改变没有产生改善时。目的：本研究旨在利用文献计量学分析，总结近十年来全球关于多囊卵巢综合征及其药物治疗的研究趋势。方法：利用Web of Science数据库对2015-2024年进行文献计量分析。针对多囊卵巢综合征及其药物治疗方案设计了搜索查询。数据分析通过可视化协作、研究趋势等在VOS查看器中进行。结果：2607篇出版物符合纳入标准。最常见的治疗主题是联合口服避孕药，二甲双胍，来曲唑和肌醇。中国是出版数量的主要贡献者，而美国被引用最多，联系最紧密。影响力似乎来自莫纳什大学，该大学的Legro RS被认为是最具影响力的机构，同时也是最具影响力的作者。结论：该研究揭示了PCOS药物治疗的全球趋势，越来越关注代谢和分子方面。主要贡献者和新兴疗法突出了多囊卵巢综合征治疗研究的扩大范围和未来潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Pharmacotherapy 医学-药学

CiteScore

5.60

自引率

3.10%

发文量

163

审稿时长

4-8 weeks

期刊介绍： Expert Opinion on Pharmacotherapy is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on newly approved/near to launch compounds mainly of chemical/synthetic origin, providing expert opinion on the likely impact of these new agents on existing pharmacotherapy of specific diseases.